<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957888</url>
  </required_header>
  <id_info>
    <org_study_id>LM2020203</org_study_id>
    <nct_id>NCT04957888</nct_id>
  </id_info>
  <brief_title>Microbial Markers for AGI</brief_title>
  <official_title>Investigation on the Microbial Biomarkers of AGI in the Early Stage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AGI is very common in ICU and sometimes will trigger the development of gut derived sepsis.&#xD;
      Thus, to find out the biomarker in early stage is very important to improve the overall&#xD;
      prognosis of critically ill patients. In this project we try to find out the microbial&#xD;
      biomarker of AGI through multi-omic technology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The AUC value of the combined markers</measure>
    <time_frame>1 year</time_frame>
    <description>The combined diagnostic accuracy of AGI through omic parameters</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">584</enrollment>
  <condition>Acute Gastrointestinal Injury</condition>
  <arm_group>
    <arm_group_label>training group</arm_group_label>
    <description>the observational group to find out the potential biomarker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>validation group</arm_group_label>
    <description>the validation group to validate the parameters used for early diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>none intervention</intervention_name>
    <description>none intervention.</description>
    <arm_group_label>training group</arm_group_label>
    <arm_group_label>validation group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ICU patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: All those critically ill patients with anticipated ICU stay for more&#xD;
        than 2 days Exclusion Criteria:Patients will be excluded if they have any of the following&#xD;
        situations: patients who have not signed the informed consent; Unable to tolerate&#xD;
        intra-abdominal pressure monitoring; pregnant woman; Patients after bladder surgery;&#xD;
        Systemic diseases and recent use of related drugs; He had a history of infectious diseases,&#xD;
        such as tuberculosis or PPD positive. History of hypertension and poor blood pressure&#xD;
        control (SBP / DBP &gt; = 140mmHg); Patients with severe mental illness; Long term use of&#xD;
        traditional Chinese medicine, probiotics, gastric mucosal protective agents, proton pump&#xD;
        inhibitors, chemotherapy or immunosuppressive drugs, etc. were not included if the drug was&#xD;
        not stopped within one month before admission.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbiome</keyword>
  <keyword>metabolome</keyword>
  <keyword>biomarker</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

